Platinum and other heavy metal compounds in cancer chemotherapy: molecular mechanisms and clinical applications

Following the serendipitous discovery of cisplatin by Barnett Rosenberg back in 1965 and its approval in 1978 by the Food and Drug Administration, a growing number of platinum compounds have emerged as fundamental components for the treatment of different types of cancer. Although replaced by the better tolerated analogue carboplatin, cisplatin itself is still an important tool for the treatment of germ cell tumors and cancers of head and neck. The introduction into the clinic of the DACH platinum compound oxaliplatin has broadened the spectrum of activity of the platinums to gastro-intestinal cancers, and especially colorectal cancer. Among the newer analogues on the way to the clinic, satraplatin is particularly interesting since it is the first orally available platinum analogue. The papers in this volume have been presented at the X International Symposium on Platinum Coordination Compounds in Cancer Chemotherapy heldin Verona, Italy, from November 30th to December 3rd 2007. http://www.ispcc2007.org/scientific.htm INDICE: From the contents Platinum chemotherapy: an oncologic success story. Platinum compounds in clinical development. Satraplatin: overview. Satraplatin in prostate cancer. New formulations. Novel drug delivery systems: AP5346.CTR1 as a determinant of platinum drug transport. ATP7B regulates intracellular sequestration of Pt drugs. Molecular alterations of oxaliplatin-resistant cell exhibiting accumulation defects. How to overcome cisplatin resistance through proton pump inhibitors. Multiple mechanisms of resistance to cisplatin in cancer cells. Platinum drug damage to DNA and nucleosomes: recognition/repair and cell-response mechanisms. Molecular rationale to improve platinum selectivity. Recognition and processing of platinum drugs-DNA adducts. Platinum drugs and DNA repair: lessons from the NCI-60 panel and clinical correlates. Effectsof platinated compounds in signal transduction: role of interaction with other drugs. Platinum drugs as radio-sensitizer.

• ISBN: 978-1-60327-458-6
• Editorial: Humana
• Encuadernacion: Cartoné
• Páginas: 310
• Fecha Publicación: 01/12/2008
• Nº Volúmenes: 1
• Idioma: Inglés